Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hypersensitivity × Lymphoid × Clear all
NCT03098589 2025-03-30

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Celgene

Completed
1,149 enrolled
Head & NeckLymphoidOther hematologic neoplasm

Sleepiness, Arrhythmias, Cardiac, Cataract, Confusion, Coronary Artery Disease, Digestive System Diseases, Dizziness, Fatigue, Heart Failure, Hemorrhage, Hypersensitivity, Hypotension, Orthostatic, Hypothyroidism, Infections, Lymphoma, Peripheral Nervous System Diseases, Seizures, Thromboembolism, Tumor Lysis Syndrome, Neoplasms, Second Primary, Lung Diseases, Interstitial, Renal Insufficiency, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Teratogenesis